Upstream Bio, Inc. (UPB)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$2.74-8.36%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Upstream Bio, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	524,057
EPS	—	-0.726
Annual ending 2026-12-31
Revenue	—	2.71M
EPS	—	-2.875
Annual ending 2027-12-31
Revenue	—	1.63M
EPS	—	-2.764

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain cash reserves near $341.5M through 2027	Upstream Bio has $341.5M cash to fund operations through 2027.	Intact	cash falls below $300M before end of 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reduce net losses toward breakeven	A supporting condition in Upstream Bio, Inc.'s published investment case. The stated target is EPS loss less negative than -$2.5 per share.	Broken	EPS loss worsens beyond -$3.0 per share in FY 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stabilize or improve revenue from current forecast	A primary condition in Upstream Bio, Inc.'s published investment case. The stated target is revenue decline less than -10% YoY.	Broken	revenue decline exceeds -10% YoY in FY 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.76

$-2.85 → $-2.76 · observed estimates

FY2027 revenueUnavailable

$0.00B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-2.85	$1,925,833	7 / 5
2026-07-25	$-2.89	$1,650,710	8 / 7
2026-07-26	$-2.85	$1,925,833	7 / 5
2026-07-27	$-2.89	$1,650,710	8 / 7
2026-07-28	$-2.89	$1,650,710	8 / 7
2026-07-29	$-2.85	$1,925,833	7 / 5
2026-07-30	$-2.89	$1,650,710	8 / 7
2026-07-31	$-2.89	$1,650,710	8 / 7
2026-08-01	$-2.85	$1,925,833	7 / 5
2026-08-02	$-2.89	$1,650,710	8 / 7
2026-08-03	$-2.89	$1,650,710	8 / 7
2026-08-04	$-2.89	$1,650,710	8 / 7
2026-08-05	$-2.85	$1,925,833	7 / 5
2026-08-06	$-2.89	$1,650,710	8 / 7
2026-08-08	$-2.85	$1,925,833	7 / 5
2026-08-09	$-2.89	$1,650,710	8 / 7
2026-08-10	$-2.85	$1,925,833	7 / 5
2026-08-12	$-2.85	$1,925,833	7 / 5
2026-08-13	$-2.85	$1,925,833	7 / 5
2026-08-14	$-2.85	$1,925,833	7 / 5
2026-08-15	$-2.85	$1,925,833	7 / 5
2026-08-16	$-2.85	$1,925,833	7 / 5
2026-08-17	$-2.85	$1,925,833	7 / 5
2026-08-18	$-2.85	$1,925,833	7 / 5
2026-08-19	$-2.85	$1,925,833	7 / 5
2026-08-20	$-2.91	$1,945,667	7 / 5
2026-08-21	$-2.76	$1,634,800	7 / 5
2026-08-22	$-2.76	$1,634,800	7 / 5
2026-08-23	$-2.76	$1,634,800	7 / 5
2026-08-24	$-2.76	$1,634,800	7 / 5
2026-08-25	$-2.76	$1,634,800	7 / 5
2026-08-26	$-2.76	$1,634,800	7 / 5
2026-08-27	$-2.76	$1,634,800	7 / 5
2026-08-28	$-2.76	$1,634,800	7 / 5
2026-08-29	$-2.76	$1,634,800	7 / 5
2026-08-30	$-2.76	$1,634,800	7 / 5
2026-08-31	$-2.76	$1,634,800	7 / 5
2026-09-01	$-2.76	$1,634,800	7 / 5
2026-09-02	$-2.76	$1,634,800	7 / 5
2026-09-03	$-2.76	$1,634,800	7 / 5
2026-09-04	$-2.76	$1,634,800	7 / 5
2026-09-05	$-2.76	$1,634,800	7 / 5
2026-09-06	$-2.76	$1,634,800	7 / 5
2026-09-07	$-2.76	Unavailable	6 / 4
2026-09-08	$-2.76	Unavailable	6 / 4
2026-09-09	$-2.76	Unavailable	6 / 4
2026-09-10	$-2.76	Unavailable	6 / 4
2026-09-11	$-2.76	Unavailable	6 / 4
2026-09-12	$-2.76	Unavailable	6 / 4
2026-09-13	$-2.76	Unavailable	6 / 4
2026-09-14	$-2.76	Unavailable	6 / 4
2026-09-15	$-2.76	Unavailable	6 / 4
2026-09-16	$-2.76	Unavailable	6 / 4
2026-09-17	$-2.76	Unavailable	6 / 4
2026-09-18	$-2.76	Unavailable	6 / 4
2026-09-19	$-2.76	Unavailable	6 / 4
2026-09-20	$-2.76	Unavailable	6 / 4
2026-09-21	$-2.76	Unavailable	6 / 4
2026-09-22	$-2.76	Unavailable	6 / 4
2026-09-23	$-2.76	Unavailable	6 / 4
2026-09-24	$-2.76	Unavailable	6 / 4
2026-09-25	$-2.76	Unavailable	6 / 4
2026-09-26	$-2.76	Unavailable	6 / 4
2026-09-27	$-2.76	Unavailable	6 / 4
2026-09-28	$-2.76	Unavailable	6 / 4
2026-09-29	$-2.76	Unavailable	6 / 4
2026-09-30	$-2.76	Unavailable	6 / 4
2026-10-01	$-2.76	Unavailable	6 / 4
2026-10-02	$-2.76	Unavailable	6 / 4
2026-10-03	$-2.76	Unavailable	6 / 4
2026-10-04	$-2.76	Unavailable	6 / 4
2026-10-05	$-2.76	Unavailable	6 / 4
2026-10-06	$-2.76	Unavailable	6 / 4
2026-10-07	$-2.76	Unavailable	6 / 4
2026-10-08	$-2.76	Unavailable	6 / 4
2026-10-09	$-2.76	Unavailable	6 / 4
2026-10-10	$-2.76	Unavailable	6 / 4
2026-10-11	$-2.76	Unavailable	6 / 4
2026-10-12	$-2.76	Unavailable	6 / 4
2026-10-13	$-2.76	Unavailable	6 / 4
2026-10-14	$-2.76	Unavailable	6 / 4
2026-10-15	$-2.76	Unavailable	6 / 4
2026-10-16	$-2.76	Unavailable	6 / 4
2026-10-17	$-2.76	Unavailable	6 / 4
2026-10-18	$-2.76	Unavailable	6 / 4
2026-10-19	$-2.76	Unavailable	6 / 4
2026-10-20	$-2.76	Unavailable	6 / 4
2026-10-21	$-2.76	Unavailable	6 / 4
2026-10-22	$-2.76	Unavailable	6 / 4
2026-10-23	$-2.76	Unavailable	6 / 4
2026-10-24	$-2.76	Unavailable	6 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	7	1
2026-06-01	8	2
2026-07-01	8	2
2026-08-01	7	2
2026-09-01	7	2
2026-10-01	6	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain cash reserves near $341.5M through 2027Direct metric needs a verified mapping
Reduce net losses toward breakevenPublished status: Broken
Stabilize or improve revenue from current forecastPublished status: Broken

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.1%Typical daily move · historical

Downside history

-91.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Upstream Bio, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

UPB is a high-risk clinical-stage healthcare company, with its longer-term case tied to potential drug development rather than established earnings. The thesis is in a watch state: management is progressing key trials, but recent financial performance trails its industry cohort and the risk label has risen to high.

What's priced into Upstream Bio, Inc.

UPB is valued at a premium to peers, and the valuation model points to a meaningful expectations gap, though confidence in that model is low. The snapshot attributes the premium to optionality, meaning value investors assign to future possibilities, but it does not show that the premium is supported by the full business picture.

What the fundamentals likely do

Near term, results may remain uneven: UPB had an earnings beat in August after an in-line report in May, while its recent performance remains below its industry cohort. Management says severe asthma and CRSwNP Phase 3 trials remain on track for Q1 2027, and VENTURE Phase 2 enrollment is complete; cash declined to about $261 million by Q2 2026, while management expects it to fund operations through 2027.

What Upstream Bio, Inc. hinges on

The multi-year case depends on starting the planned Phase 3 trials, advancing COPD toward Phase 3, and maintaining enough cash to fund operations through 2027. Near-term risks include a guidance cut, weaker jobs data and recession fears, and the litigation filed in September; stronger earnings and guidance from healthcare bellwethers could support the sector backdrop.